|
Jul 15
|
Alkermes to Report Second Quarter Financial Results on July 29, 2025
|
|
Jul 15
|
DoorDash, Southwest downgraded: Wall Street's top analyst calls
|
|
Jul 14
|
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
|
|
Jul 14
|
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19%
|
|
Jul 10
|
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
|
|
Jul 10
|
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
|
|
Jul 9
|
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
|
|
Jul 1
|
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
|
|
Mar 14
|
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?
|
|
Mar 14
|
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment?
|
|
Mar 14
|
Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years
|
|
Mar 13
|
Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says
|
|
Mar 1
|
Alkermes plc (ALKS): Among the Best Psychedelic Stocks to Buy in 2025
|
|
Feb 26
|
Alkermes to Participate in Upcoming Investor Conferences
|
|
Jan 13
|
Onera’s validation trial of home polysomnography sleep device succeeds
|
|
Jan 2
|
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Dec 31
|
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)?
|
|
Oct 12
|
Is Alkermes (ALKS) The Most Undervalued Quality Stock To Buy According To Analysts?
|
|
Oct 9
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
Oct 2
|
Alkermes (NASDAQ:ALKS) shareholder returns have been favorable, earning 62% in 5 years
|